Loibl et al evaluated AR expression and the pCR rate in the phase III GeparTrio trial which showed the pCR rate was 25.4% in patients with AR negative breast cancer but only 12.8% in patients with AR positive breast cancer 23. This evidence concerns the gene AR and breast carcinoma.